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Abstract 
Purpose: 
A novel [68Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-
Ala-Val-Gly-His-Sta-Leu-NH2 peptide (BAY86-7548) having high affinity to bombesin 
receptor subtype 2 to detect primary and metastatic prostate carcinoma (PCa) using PET/CT 
was synthesized and evaluated for prostate cancer (PCa). 
 
Experimental Design: 
In this first human study with BAY86-7548, fourteen men scheduled for radical 
prostatectomy (n=11) or with biochemical recurrence after surgery or hormonal therapy (n=3) 
were enrolled. The patients received an intravenous injection of BAY86-7548 followed by 
over 60-minute dynamic imaging of prostate gland (n=10) and/or subsequent whole-body 
imaging (n=14). The visual assessment of PET/CT images included evaluation of 
intraprostatic (12 subsextants) and pelvic nodal uptake of BAY86-7548 in 11 surgical patients 
and detection of potential metastatic foci in all patients. In patients with biochemical 
recurrence, results were compared to those of either [11C]-acetate (n=2) or [18F]-
fluoromethylcholine (n=1) PET/CT. 
 
Results: 
Using histology as gold standard, an increase in sensitivity, specificity, and accuracy 
for detection of primary PCa was observed (88%, 81% and 83%, respectively). In addition, 
sensitivity for detecting metastatic lymph nodes was increased by 70%. BAY86-7548 
correctly detected local recurrence in prostate bed and showed nodal relapse in accordance 
with [11C]-acetate PET/CT in two patients with biochemical relapse. In the third hormone 
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refractory patient, BAY86-7548 failed to show multiple bone metastases evident on  [18F]-
fluoromethylcholine PET/CT. 
 
Conclusion: 
BAY86-7548 PET/CT is a promising molecular imaging technique for detecting 
intraprostatic PCa. 
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Translational Relevance  
Overexpression of bombesin receptors has been observed in several neoplastic 
diseases, including prostate cancer (PCa), thus offering a promising target for in vivo imaging. 
Anatomic imaging often fails to detect local disease with sufficient specificity for emerging 
focal therapies for PCa. Therefore, novel techniques showing the dominant intraprostatic 
lesion are becoming increasingly important. This study shows that 68Ga-labeled DOTA-4-
amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 -peptide 
(BAY86-7548) PET/CT detects organ-confined PCa with an accuracy of 83%, which is at 
least comparable to multiparametric MRI and PET/CT using radiolabeled choline or acetate. 
Autoradiography findings obtained from surgical specimens indicated that BAY86-7548 
indeed detects bombesin receptor subtype 2 (gastrin-releasing peptide receptor, GRPr) 
positive lesions and could assist in planning of focal treatment of PCa. 
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Introduction 
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second most 
common cause of cancer deaths among men (1). Prostate specific antigen (PSA) and digital 
rectal examination are the first-line investigations in evaluating the risk of PCa while 
diagnosis is mainly based on transrectal ultrasound (TRUS) -guided biopsies. Due to low 
diagnostic accuracy of TRUS, many doctors prefer systematic biopsies for detection of PCa 
(2). However, about 25-35% of cancers are missed on first systematic biopsy (3, 4) and the 
Gleason score, which characterizes the malignant potential of PCa, is commonly 
underestimated (5). In addition, attempts to improve PCa detection by intensifying the biopsy 
technique have failed and seem to increase the risk of complications (6). Therefore, better 
imaging tools are needed to detect clinically significant cancer foci and to avoid unnecessary 
biopsies. Moreover, precise localization of cancer is needed to improve and further develop 
local prostate gland sparing therapies. 
Multiparametric magnetic resonance imaging (MRI) has been shown to improve 
diagnostic accuracy in the evaluation of intraprostatic PCa (7). Nevertheless, due to different 
imaging protocols, technical factors and study populations, the variability in the reported 
sensitivities and specificities remains high. (7, 8).  
Positron emission tomography (PET) is frequently used in oncology but its role in 
diagnosis of primary PCa is not well-established. The most common tracer, 18F-labeled 
fluorodeoxyglucose ([18F]-FDG), has a low sensitivity for detecting early PCa due to the low 
glucose consumption (9, 10), limiting the possibility to detect clinically localized disease. 
Other tracers, such as 18F- or 11C-labeled choline and [11C]-acetate, are used mainly for the 
diagnosis of recurrent (11-13) or metastatic (14) PCa. Their feasibility in primary diagnosis is 
limited due to uptake in benign tissue, such as benign prostatic hyperplasia (BPH) (15, 16).  
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68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2 (BAY86-7548) is a synthetic bombesin receptor antagonist, which targets 
gastrin-releasing peptide receptors (GRPr) (17). GRPr proteins are highly overexpressed in 
several human tumors, including PCa (18). Due to their low expression in BPH and 
inflammatory prostatic tissues (19, 20), imaging of GRPr has potential advantages over 
current choline- and acetate-based radiotracers. Indeed, preclinical studies using BAY86-7548 
have shown a high and persistent tracer uptake in mice bearing PC-3 tumor xenografts, which 
represent androgen-independent human PCa with high GRPr expression (21). 
The aim of this prospective, multi-site study was to investigate the safety, tolerability 
and accuracy of BAY86-7548 in detection of primary PCa and lymph node metastases in 
patients scheduled for radical retropubic or robot-assisted laparoscopic prostatectomy. In 
addition, feasibility of detecting recurrent PCa in comparison to [18F]-fluoromethylcholine, 
[11C]-acetate PET/CT or MRI was examined in three patients with rising PSA after radical or 
palliative treatment. Finally, the potential of BAY86-7548 to study GRPr expression in 
human PCa was studied. 
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Materials and Methods 
 
Patients and study design 
Eleven patients (mean age, 63 years; range, 48−72 years) with histologically confirmed 
prostate adenocarcinoma, diagnosed through systematic TRUS-guided biopsies, and three 
patients (mean age, 67 years; range, 51−82 years) with biochemical recurrence of PCa were 
prospectively enrolled. Individual patient characteristics are presented in Table 1. Thirteen 
patients were studied in Turku, Finland and one in Zurich, Switzerland. Additional inclusion 
criteria for patients undergoing radical prostatectomy were presence of cancer in at least 20% 
of biopsy material and patient preference to undergo radical surgery including pelvic 
lymphadenectomy after discussion of the treatment options with the study urologist (E.K.). 
None of the patients studied in Turku had received any hormonal or radiation therapy while 
the patient in Zurich was in androgen-resistant phase after pelvic radiotherapy, several local 
palliative radiotherapies and antiandrogenic therapy. In addition, a multiparametric 3T MRI 
using surface coil was performed for three patients (no. 9, 11 and 12) and [11C]-acetate 
PET/CT in three patients (no. 11, 12 and 13). The patient in Zurich (no. 14) underwent [18F]-
fluoromethylcholine PET/CT. Multiparametric 3T MRI consisted of anatomical T2- and T1-
weighed images, dynamic contrast-enhanced MRI and diffusion-weighed imaging. 
The study protocol was approved by the local ethics committees in Turku and Zurich as 
well as the respective authorities and each patient gave written informed consent for 
participation in the study. The entire study was conducted according to the guidelines of the 
Declaration of Helsinki. 
 
 
Synthesis of BAY86-7548  
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The precursor, DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-
Gly-His-Sta-Leu-NH2 (BAY86-7547), was obtained from Bayer HealthCare Pharmaceuticals 
(Berlin, Germany). All the other reagents were purchased from commercial suppliers and 
were synthesis or analytical grade. 
Turku. The radiosynthesis was performed with fully automated synthesis device 
(Modular Lab, Eckert & Ziegler Eurotope GmbH, Berlin, Germany). 68Ga was obtained from 
a 68Ge/68Ga generator (IGG-100, 50 mCi (1850 MBq), Eckert & Ziegler Isotope Products, 
Valencia, CA, USA) by eluting the generator with 7 mL of 0.1 M HCl. The radioactive 
fraction of the 68Ga eluate (1.6 mL) was collected and the HEPES–buffered BAY86-7547 (28 
µg, 17 nmol) was added. The reaction mixture was incubated at 100−120°C for 12.5 min 
followed by SepPak purification, sterile filtration and formulation with sterile phosphate-
buffered saline (PBS). The identity and the radiochemical purity of the product (BAY86-
7548) were evaluated by radio-HPLC. The identity was confirmed by comparing the retention 
times of the peaks obtained from BAY86-7548 and BAY86-7547. The in vitro stability of 
BAY86-7548 was tested in formulation solution (PBS) by incubating for 2 h at room 
temperature followed by radio-HPLC analysis. 
Zurich. The radiosynthesis was comparable to that in Turku except for the 68Ga eluate, 
which was trapped onto a cation-exchange cartridge (Strata-X-C, Phenomenex). Then, 0.4 mL 
of 98% acetone/0.02 M HCl was used to elute 68Ga from the cartridge. The peptide BAY86-
7547 (28 µg, 17 nmol) and uric acid were dissolved in 2 mL 0.2 M sodium acetate buffer and 
prefilled into the reaction vessel. This was followed by incubation of the reaction mixture at 
95°C for 6 min 40 sec and formulation and in vitro stability testing in saline instead of PBS. 
Otherwise, the procedures were similar. 
 
BAY86-7548 PET/CT imaging 
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The patients were imaged in supine position using a GE Discovery VCT (Turku) or 
ST16 (Zurich) PET/CT Scanner (General Electric Medical Systems, Milwaukee, WI, USA). 
Low-dose CT protocol (120 kV, 10–80 mA, noise index 25, slice thickness 3.75 mm in Turku 
and 140 kV, 10–80 mA, noise index 11.75, slice thickness 3.75 mm in Zurich) was performed 
and also used for attenuation correction. A median dose of 147 MBq (range, 108−161 MBq) 
of BAY86-7548 was injected as an intravenous bolus . During imaging the vital signs were 
monitored including a 12-lead electrocardiogram, and blood and urine chemistry. The 
measured data were corrected for dead time, decay and photon attenuation and reconstructed 
into 256 × 256 matrix. Image reconstruction followed a fully 3D VUE Point GE algorithm 
incorporating random and scatter correction with two iterations and 28 subsets. The post filter 
was 3.00 mm FWHM (full-width at half-maximum) and the field of view diameter was 700 
mm yielding to image pixel size of 3 mm. The final in-plane resolution of both PET/CT 
systems was 5 mm.  
Surgical patients (n = 11). Urethral catheter was used in 9 (82%) patients in order to 
limit accumulation of BAY86-7548 in bladder and to allow better visualization of urethra on 
PET/CT images. Tracer injection was immediately followed by dynamic PET acquisition of 
the lower pelvic area over 60 min in 10 patients. A static whole-body emission scan (7 bed 
positions, 420 s per bed position) covering the whole torso in caudal to cephalic direction was 
then acquired 69 ± 3 min after tracer injection. In addition, 6 patients had a second static PET 
of pelvic area (1 bed position of 420 s duration) 102 ± 7 min after injection. Patient no. 1 had 
static PET emission scan covering pelvic area 58 min after injection immediately followed by 
whole-body imaging. 
Biochemical recurrence (n = 3). Two patients with suspicion of recurrent PCa (no. 12 
and 13) had static PET emission scan covering whole-body 58 min after tracer injection. The 
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third patient with suspicion of bone metastases (no. 14) received whole-body imaging starting 
60 min from injection.  
 
BAY86-7548 PET/CT image analysis 
An experienced nuclear medicine physician (J.K.) and a medical student (I.J.) 
interpreted the PET/CT images in Turku in consensus. Both examiners were aware of the PCa 
diagnosis or suspicion of cancer recurrence, but were blinded to clinical and histopathological 
findings. PET/CT images in Zurich were interpreted by an experienced nuclear medicine 
physician (N.S.). In patients with primary PCa, a region-based analysis was used. The prostate 
gland was divided into three parts in superior-inferior axis. Each third was further divided into 
4 quadrants (anterior, posterior, left, right). Presence of PCa on PET/CT images was defined 
as any mono- or multifocal uptake greater than adjacent background in more than one slice 
within the CT-defined prostate gland area. In addition to region-based analysis, lesion-based 
analysis was performed in which each abnormal focus was correlated with prostatectomy 
findings to define its histopathological nature. Finally, regions of interest (ROIs) were placed 
on visually identified abnormal foci as well as areas defined as BPH and normal prostate 
tissue of the peripheral zone based on histopathological findings from whole-mount 
prostatectomy samples. Maximum standardized uptake value (SUVmax) and mean 
standardized uptake value with a 60% threshold (SUVmean) were determined in all ROIs. 
Tumors with the largest diameter of more than 0.5 cm were included into the analysis. The 
diagnostic accuracy of BAY86-7548 PET/CT was assessed using whole mount prostatectomy 
sections. In patients with biochemical recurrence, additional imaging modality was performed 
to clarify the findings of BAY86-7548 PET/CT. 
 
Surgery 
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 Open radical retropubic (n = 2) or robot-assisted laparoscopic prostatectomy (n = 9) 
and bilateral extended iliacal lymphadenectomy was performed 4 to 34 days after BAY86-
7548 imaging. Preoperative risk of lymph node metastasis was estimated using Briganti 
nomograms (22). The surgeon (E.K.) was aware of the result of BAY86-7548 imaging and 
was encouraged to harvest especially the PET/CT positive lymph nodes. The routine area 
resected was defined as follows: Lateral border of excised fibrofatty tissue was pelvic wall 
and external and common iliac artery to the ureteral crossing, medial border was perivesical 
fat, inferior border was femoral canal and superior border was ureter. In addition, the 
fibrofatty tissue from both obturator fossa and next to internal iliac artery was removed.. 
Patient no. 3 had incomplete lymphadenectomy due to cardiopulmonary instability at the end 
of operation. Patient no. 8 showed suspicious metastatic lymph nodes outside routine 
lymphadenectomy area, just above aortic bifurcation on BAY86-7548 PET/CT and had also 
these nodes resected. These nodes were not detected on preoperative CT.  
 
Histopathological analysis 
Histologic slides were analyzed by two experienced pathologists (K.A., M.K.). After 
radical prostatectomy, the prostate glands were fixed in 10% buffered formalin for 24−48 
hours. After fixation, the, left, right and anterior surfaces were inked with different colors to 
preserve the orientation of the prostate gland and to allow correlation with PET/CT images. 
Whole-mount axial macro-sections were obtained at 8-mm intervals transversely in a plane 
perpendicular to the long axis of the prostate gland in superior-inferior direction. The most 
apical macro-section was further sectioned in coronal orientation for easier evaluation of the 
capsular status of the inferior region. The first transversal section at the base was further 
sectioned in sagittal orientation for easier evaluation of the margin and seminal vesicles. Four 
μm whole-mount sections from each macro-section were stained with hematoxylin and eosin. 
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The presence and location of cancer foci, high-grade prostate intraepithelial neoplasm 
(HGPIN), prostatitis, BPH, capsular status and seminal vesicle invasion were determined. 
Gleason score was assessed as combination of the most common and the second most 
common type of Gleason grading for each tumor focus. 
 
GRP receptor autoradiography  
Fresh tissue samples of 1.5 × 1.5 × 0.5 cm size for autoradiography (ARG) were taken 
from right and left lobe of prostate gland in 10 patients. Patient no. 2 had two fresh tissue 
samples from each lobe while the remaining patients had only one per each lobe. The samples 
were immediately frozen at -70°C. Cryostat sections (20 μm thick) of these samples were 
processed for receptor ARG as described previously for other peptide receptors (22) using 
GRPr-specific [125I]-Tyr4-bombesin as radioligand (23). Tissue sections were mounted on 
precleaned microscope slides and stored at −20°C for at least 3 days to improve adhesion of 
tissue to the slide. Sections were then processed according to Vigna et al. (23). They were first 
preincubated in 10 mM HEPES buffer (pH 7.4) for 5 min at room temperature followed by 
incubation in 10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl2, 1 mM 
ethyleneglycol-bis (β-aminoethylether)-N-N9-tetraacetic acid, 0.1% BSA, 100 mg/mL 
bacitracin (pH 7.4), and approximately 100 pM [125I]-Tyr4-bombesin-14 (81.4 TBq/mmol; 
PerkinElmer, Turku, Finland) in the presence or absence of 1 mM bombesin for 1 h at room 
temperature. After incubation, the sections were washed four times for 2 min in 10 mM 
HEPES with 0.1% BSA (pH 7.4) at 4°C. Finally, the slides were rinsed twice for 5 sec at 4°C 
in distilled water, dried at room temperature, and placed in apposition to imaging plates (Fuji 
Imaging Plate BAS-TR2025, Fuji Photo Film Co., Ltd., Tokyo, Japan) for 14 days for 
scanning with the Fuji Analyzer FLA-5100. Sections were stained with hematoxylin-eosin to 
localize the areas of BPH, PCa and HGPIN. 
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Statistical analysis 
Statistical analysis was performed with SAS, version 9.3 (SAS Institute Inc., Cary, NC, 
USA). SUV measurements were compared using Bonferroni multiple comparison test (24). 
Normal distributions were assessed by the Kolmogorov and Smirnov method. A p-value 
below 0.01 was considered to be statistically significant.  
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Results 
Patients’ clinical findings are summarized in Table 1. No drug-related adverse events 
were associated with BAY86-7548 and all patients tolerated the imaging procedure well. The 
mean PSA level of patients with primary PCa was 18 ± 11 ng/mL (range, 6.2−45.0 ng/mL), 
while the three patients with biochemical recurrence of PCa had PSA levels of 0.36, 4.7 and 
282 ng/mL. Based on histopathological analysis of whole-mount prostatectomy samples, 26 
tumor foci were identified in 11 patients, with 19 (73%) of these foci larger than 0.5 cm. 
BAY86-7548 demonstrated fast excretion through kidneys with 25% of injected 
radioactivity dose observed in urine 30 min after injection. Plasma pharmacokinetics, whole-
body distribution, metabolism and radiation dosimetry of BAY86-7548 in healthy men have 
been previously described (25). The highest radioactivity uptake was detected in the urinary 
bladder and pancreas, which is in the line with the known expression of GRPr and previous 
preclinical studies with RM2 peptide (21). Maximum peak uptake of the total injected 
radioactivity was seen in the urinary bladder and liver, 36% and 19%, respectively. 
 
Preparation of BAY86-7548 
The radiopharmaceutical BAY86-7548 was obtained with a moderate yield (440 ± 120 
MBq, n = 13). Radioactivity concentration and specific radioactivity at end of synthesis 
(EOS) were 44 ± 13 MBq/ml and 26 ± 7 GBq/µmol, respectively. Radiochemical purity was 
at least 97% and the difference between retention times of HPLC peaks obtained from 
BAY86-7547 and BAY86-7548 was 0.19 ± 0.07 min. The tracer remained radiochemically 
stable for 2 hours in formulation solution at room temperature; radiochemical purity was 98 ± 
0% at 1 hour after EOS and 98 ± 1% at 2 hours after EOS (mean ± SD, n = 3). Every injected 
batch of BAY86-7548 fulfilled the release criteria. 
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Diagnostic accuracy of cancer detection  
Region-based analysis of BAY86-7548 PET/CT findings in 132 regions, of which 57 
(43%) contained cancer according to histopathological analysis, revealed 63 regions as 
positive and 69 as negative. Using histology as gold standard, 49 of these were considered 
true-positive and 61 true-negative, yielding a sensitivity, specificity, and accuracy of 89%, 
81%, 83%, respectively. Lesion-based analysis of BAY86-7548 PET/CT revealed 15 true-
positive tumor lesions, 6 false-positive lesions, and 4 false-negative lesions resulting in a 
sensitivity of 79%. The 6 false-positive intraprostatic lesions were determined to be BPH 
based on whole mount prostatectomy sections. BAY86-7548 PET/CT successfully detected 
all dominant lesions except one anterior lesion. However, another smaller peripheral zone 
tumor of the same patient (no. 2) was detected. Both of the lesions had the Gleason score of 
3+4. 
 
Detection of lymph node metastasis  
Primary PCa with at least one metastatic lymph node was present in three (27%) out of 
eleven patients undergoing prostatectomy with lymph node dissection. In total, 135 lymph 
nodes were histopathologically analyzed with 10 showing the presence of metastatic PCa. Per 
patient sensitivity was 67% and per node sensitivity was 70% for BAY86-7548 PET/CT. The 
sizes of the three BAY86-7548 negative metastases were 6 mm (patient no. 1, left iliac node), 
5 mm and 5 mm (patient no. 6, two right iliac lymph nodes). Patient no. 6 had in addition one 
correctly detected metastatic left iliac node (size 11 mm). Two normal-sized lymph nodes 
(less than 10mm) were removed from patient no. 8 above the aortic bifurcation based on 
guidance of BAY86-7548 PET/CT (see Surgery). Both of these were histopathologically 
confirmed as PCa metastases (Figure 1). 
 
Research. 
on March 14, 2014. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 9, 2013; DOI: 10.1158/1078-0432.CCR-12-3490 
 17
Quantitative analysis 
The average SUVmax and SUVmean were 6.6 ± 4.7, 5.1 ± 3.7, respectively, for 
histologically confirmed cancer foci as measured 60–70 min after injection. These values 
were different from the SUVmax and SUVmean of BPH (2.4 ± 1.5, 1.8 ± 1.2, respectively) and 
normal tissue of peripheral zone (1.3 ± 1.0, 1.0 ± 0.9, respectively) (p<0.01for all 
comparisons). No significant difference in SUVmax and SUVmean of BPH and normal tissue of 
peripheral zone was observed. See Figure 2. 
 
Results of autoradiography 
  PCa was present in 15 (68%) autoradiography sections. All lesions were positive by 
autoradiography. BPH nodules in two tissue sections and HGPIN lesion in one tissue section 
were positive, indicating the presence of GRPr expression (Figure 3). 
 
Patients with clinical suspicion of recurrent disease 
 BAY86-7548 PET/CT successfully detected recurrence of PCa in the two hormone-
naive patients with biochemical recurrence (no. 12 and 13). The findings were in concordance 
with [11C]-acetate PET/CT and 3T MRI in prostate bed in patient no. 12. By contrast, both 
[11C]-acetate PET/CT and diffusion-weighted MRI suggested the presence of metastatic 
parailiac lymph node while BAY86-7548 PET/CT did not show any pathological uptake in 
this region. The patient subsequently received radiotherapy to PET and MRI positive prostatic 
bed and parailiac nodes bilaterally. In a repeated [11C]-acetate PET/CT 3 months from 
radiotherapy, PSA was 0.068 and the prostate bed had turned [11C]-acetate negative while the 
parailiac lymph node was still positive. On CT, this node measured 6 mm and remained 
unchanged before and after radiotherapy in spite of rapid decrease in serum PSA. In patient 
no. 13, BAY86-7548 was positive in one iliac and one mediastinal node, which were similarly 
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positive on [11C]-acetate. In addition, [11C]-acetate showed several positive lymph nodes in 
unconventional locations such as axillary, parasternal and inguinal regions. The single patient 
imaged in Zurich (no. 14) had multiple [18F]-fluoromethylcholine positive bone metastases 
and his BAY86-7548 PET/CT was totally negative. 
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Discussion 
With the evolution of local and minimally invasive therapies for PCa, such as focal 
radiotherapy and high-intensity focused ultrasound, a pressure to develop better diagnostic 
tools to detect primary PCa is evident. Currently, multiparametric MRI is being increasingly 
utilized in imaging of local PCa to plan focal therapies (7, 8). Combination of functional and 
anatomical information using hybrid PET/MRI imaging can be a powerful technique provided 
that the applied tracer and the chosen MRI acquisition protocol are optimized for each patient 
individually.  
Because none of the currently available positron emitting tracers can reliably detect 
early PCa or identify the extent of intraprostatic disease, there is a demand for more specific 
tracers. An ideal tracer would detect the dominant PCa lesion and differentiate cancer from 
BPH and inflammatory lesions. We studied a novel 68Ga-labeled bombesin antagonist 
BAY86-7548 to translate the encouraging pre-clinical findings (21) to identical results in 
patients scheduled for radical prostatectomy or with biochemical recurrence. We were 
specifically interested in the uptake of BAY86-7548 in intraprostatic lesions and in the 
potential of the peptide tracer to detect metastatic lymph nodes. By selecting 68Ga as the 
radionuclide, we were able to perform the study without access to cyclotron. 
The potential of 68Ga-labeled peptides to target tumor receptors has been previously 
demonstrated in the case of somatostatin receptor imaging. Due to their higher sensitivity and 
better biodistribution properties (26, 27), [68Ga]-DOTATOC, [68Ga]-DOTANOC, and [68Ga]-
DOTATATE are used for diagnosis of neuroendocrine tumors and are gradually replacing 
conventional gamma emitting radioisotope techniques in Europe. In general, peptides provide 
excellent characteristics for PET imaging due to their easy synthesis, fast and specific 
targeting features and rapid clearance from the body mainly via the renal pathway. Much like 
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somatostatin receptors, peptides targeting G-protein coupled receptors are effectively 
accumulating in tumors in vivo.  
The GRPr, also named bombesin receptor subtype 2, is a G-protein coupled seven-
transmembrane receptor belonging to the bombesin receptor family with four subtypes (for 
review, see (17)). GRPr proteins are highly overexpressed in several human tumors, including 
PCa, breast cancer, small cell lung cancer (SCLC) and non-SCLC, as well as renal cell cancer 
(18). Our results with radiolabeled bombesin antagonist (BAY86-7548) indicate that this 
tracer could be more PCa-specific than imaging with [18F]-, [11C]-choline or [11C]-acetate, 
which generally depict lipid metabolism and accumulate also in BPH and inflammatory 
conditions. Bombesin receptor antagonists may be preferable to agonists for tumor imaging 
due to higher tumor uptake and longer tumor washout time (28). In addition, bombesin 
receptor antagonists have reduced physiologic activity and radioactivity accumulation at 
physiologic GRPr targets, which potentially imply fewer side effects (28).  
 Despite the variety of bombesin compounds synthesized and evaluated, none have 
been systematically evaluated in patients with PCa. The study by Van de Wiele et al. using 
[99mTc]-527RP scintigraphy targeting GRPr, had only four patients with metastatic PCa. One 
of these patients had specific uptake of [99mTc]-527RP in PCa metastasis (29). In the current 
study, 68Ga-labeled bombesin antagonist BAY86-7548 had encouraging results in detection of 
primary PCa by having an accuracy of 83% for detection of the organ-confined disease. 
Notably, a significant difference was observed in SUV between cancerous and hyperplastic 
lesions. This is an encouraging finding, since non-specific uptake in benign prostatic lesions is 
one of the major limitations of radiolabeled choline or acetate. However, fusion of anatomical 
MRI with [18F]-, [11C]-choline or [11C]-acetate PET can only partly overcome this limitation 
(30). Apart from some small cancer foci, 10 out of 11 dominant lesions were detected positive 
with BAY86-7548.  
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In detection of lymph node metastases a sensitivity of 70% was observed. Although 
limited, it is not inferior to that seen in [18F]-fluoromethylcholine or [11C]-acetate PET/CT 
imaging or multiparametric MRI. In addition to the lack of expression of GRPr in a particular 
lesion, there are two explanations for this less-than-optimal sensitivity. Firstly, small and 
diffusely growing metastatic deposits or primary foci can be missed if the tumor-specific 
uptake is low due to partial volume effects. Secondly, the physical characteristics of 68Ga with 
its average positron range between 2−3 mm are less ideal than those of the more widely used 
radionuclides, such as 18F (31). Due to the low number of patients with biochemical 
recurrence, the potential of BAY86-7548 in diagnosis of recurrent PCa remained 
inconclusive. Finally, most of our patients undergoing a surgery belonged to the high clinical 
risk group with high risk of lymph node metastasis. This resulted in relatively high percentage 
(43%) of regions containing cancer according to histopathological analysis and a selection 
bias embedded to the study inclusion criteria could not be completely avoided. Since whole-
mount axial macro-sections were obtained at 8-mm intervals, some small PCa lesions could 
have been missed and the diameter of larger cancer lesions could have been underestimated. It 
is well known that precise correlation of PCa location on whole-mount prostatectomy to 
PET/CT and MRI is relative difficult (32). Anatomical landmarks, such as urethra, were used 
to enable the correlations of whole-mount prostatectomy to PET/CT images. Although no 
cross-calibration of the two PET/CT scanners was performed, the consequences are 
considered minimal since only one patient was studied using a different PET/CT scanner. 
 Although radiolabeled choline or acetate remain the most commonly used tracers for 
imaging of biochemical relapse, these tracers have shown only limited accuracy in detection 
of primary PCa (15, 16). In a recent study including 39 patients undergoing radical 
prostatectomy, multiparametric MRI showed a sensitivity of 82% for detection of PCa lesions 
greater than 0.5 cm while the sensitivity of [11C]-acetate PET/CT was only 62% (33). 
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Similarly, MRI including MR spectroscopy has been shown to outperform [11C]-choline 
PET/CT in evaluation of primary disease (34) and multiple studies have demonstrated low 
specificity of radiolabeled choline or acetate for PCa imaging due to uptake in BPH (15, 16, 
33). Currently, none of these 18F- or 11C-labeled tracers, which are metabolized in the 
phospholipid synthesis pathway, can be recommended for evaluation of primary PCa (35). 
Therefore, the 83% accuracy of BAY86-7548 PET/CT observed in this study is indeed 
encouraging. When combined with multiparametric MRI, BAY86-7548 PET/CT may result 
in sufficient diagnostic performance to allow focal treatment of intraprostatic lesions of PCa. 
Despite the relatively small number of patients, we have demonstrated the feasibility 
of BAY86-7548 PET/CT for detection of organ-confirmed PCa. Our histopathological and 
autoradiography analyses indicated that 68Ga-labeled bombesin antagonist BAY86-7548 had 
high PCa binding specificity with significantly higher uptake in PCa compared to benign 
tissue. BAY86-7548 was well tolerated by all patients. This new tracer could be more 
accurate in detection of primary and recurrent PCa than previously used positron emitting 
tracers, although its feasibility in imaging of metastatic disease requires further optimization.  
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Table 1. Patient characteristics 
Patient 
 
 
 
Age 
 
 
 
Injected 
radio-
activity 
 
 
Post-
operative 
TNM 
 
 
Prostate 
gland 
weight 
 
 
                 
Gleason  Scored  
PSA 
at 
imaging 
 
 
Preoperative 
risk of N+ 
disease 
 
No. of 
PCa 
lesions 
 
 
Size of 
dominant 
lesion 
 
Proportion 
of cancer 
in prostate 
gland 
 
No. of 
metastatic 
/ 
recovered 
lymph 
nodes 
 
Settinga 
 
 
 
 ARGc 
 
 
Final 
 
 
no. (yrs)  (MBq)   (g) right/left (ng/mL) (% ) (mm) (%)
1 62 161 T3bN1 54 0/3+4 4+3 16 30 2 17 30 1/15 P 
2 57 160 T3aN0 59 3+3/3+4 3+4 6.9 7 3 16 30 0/14 P 
3 72 150 T3bN0 152 3+3/3+3 4+3 45 28 2 26 20 0/3 P 
4 69 159 T3bN0 55 0/4+4 3+4 21 60 1 19 20 0/7 P 
5 63 154 T3aN0 47 3+4/3+3 4+3 6.2 17 2 16 20 0/13 P 
6 62 153 T3bN1 35 3+3+4+4 4+4 15 22 3 12 20 3/13 P 
7 64 148 T2cN0 32 3+4/4+3 3+4 17 22 1 35 20 0/20 P 
8 66 146 T4N1M1 54 5+4/5+4 5+4 14 33 1 32 60 6/17 P 
9 66 158 T3aN0 101 0/0 4+3 13 26 2 12 7 0/8 P 
10 48 147 T2cN0 32 0/3+4 3+4 10 16 1 22 25 0/15 P 
11 64 129 T3aN0 66 N/A 4+4 29 78 1 20 10 0/10 P 
12 52 143 T3bN0M0 N/A N/A 4+4 0.36 N/A N/A N/A N/A N/A R 
13 67 108 T2cN0M0 N/A N/A 4+5 4.7 N/A N/A N/A N/A N/A R 
14 82 152 T2N1M0 N/A N/A 2+3 282 N/A N/A N/A N/A N/A R 
Mean 64 147            
SD 8 15   
 
a - P, primary cancer, R, recurrence; b - N/A, not applicable; c – ARG, autoradiography; d – Final Gleason score is based on the whole 
mount prostatectomy while ARG Gleason score is from the particular tissues section used for ARG. 
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Figure legends 
Figure 1. Coronal (A) and axial views (B,C) of BAY86-7548 PET/CT in patient no. 8 
with PCa metastasis to multiple lymph nodes. Two normal-sized (less than 10 
mm) nodes above the aortic bifurcation indicated with red arrow showed 
increased uptake of tracer, SUVmax 6.2 and 6.3. In addition, one left parailiac 
node, SUVmax 12.7, (B) and two right parailiac nodes, SUVmax 6.1 and 4.7, (C) 
showed increased uptake of BAY86-7548. These five lymph nodes were 
histologically confirmed as metastases at surgery. Green arrows point to 
ureters, which can be easily distinguished on anatomic CT. Images are scaled 
to SUV, with a minimum at 0 and maximum at 5. 
 
Figure 2.  Maximum (A) and mean (B) standardized uptake value (SUV) of BAY86-7548 
in carcinoma, benign prostatic hyperplasia (BPH) and normal prostate gland 
tissue in 11 patients scheduled for radical prostatectomy. Significantly higher 
uptake expressed as SUVmax and SUVmean of cancer foci was found compared to 
both BPH and normal tissue of peripheral zone. N.S. –not significant  
 
Figure 3. BAY86-7548 PET/CT (A) of patient no. 10 showing uptake in the left lobe of 
prostate gland in the area of cancer based on whole mount prostatectomy 
sample (B - tumor is outlined in blue. (Bar, 1 cm). Autoradiography showed 
presence of GRPr in the section taken from the left lobe (D upper part. Bar, 1 
cm) in the area of cancer (C upper part - tumor is outlined in blue. Bar, 1 cm), 
while only small areas of high-grade prostate intraepithelial neoplasm (HGPIN) 
in the section taken from the right lobe had positive activity (C, D lower part - 
red arrow points to the area of HGPIN. Bar, 1 cm). The presence of 1 mM 
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bombesin blocked uptake of [125I]-Tyr4-bombesin-14 in the sections from left 
(D upper right part) and right (D lower right part) lobe. BAY86-7548 PET/CT 
image is scaled to SUV, with a minimum at 0 and maximum at 5. 
 
Figure 4. The uptake of BAY86-7548 in patient no. 3 was localized in the peripheral 
(yellow arrow in A) and central zone (red arrow in A). These areas coincide 
well with cancer (outlined in blue) on corresponding prostatectomy sections (B 
- Bar, 1 cm). The large BPH nodules in the central zone did not show uptake of 
BAY86-7548. Black arrow points to urinary activity in a urethral catheter. The 
weight of the prostate gland immediately after prostatectomy was 152 g. Image 
is scaled to SUV, with a minimum at 0.5 and maximum at 5. 
 
Figure 5. Pre-operative fusion of diffusion-weighted imaging (b = 750 s/mm2) with T2-
weighted MRI (A), BAY86-7548 PET/CT (B) and [11C]-acetate PET/CT (C) 
showed suspicious presacral metastatic lymph node in patient no. 11. BAY86-
7548 SUVmax of the node was 2.0. Unfortunately, the node could not be 
accessed during robotic prostatectomy and remained positive on post-surgical 
[11C]-acetate PET/CT (D) as did the patient’s PSA (1.9). The preoperative 
[11C]-acetate SUVmax of the suspicious node was 2.5 while post-surgical was 
6.2. Subsequently endocrine therapy was started. Please note uptake of [11C]-
acetate in pelvic muscles not seen in BAY86-7548 PET/CT images. BAY86-
7548 image is scaled to SUV, with a minimum at 0 and maximum at 5 while 
[11C]-acetate images C and D are scaled to SUV, with a minimum at 0, 0 and 
maximum at 3.6, 10.9, respectively.  
Research. 
on March 14, 2014. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 9, 2013; DOI: 10.1158/1078-0432.CCR-12-3490 
Figure 1
R
esearch. 
o
n
 M
arch 14, 2014. © 2013 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on August 9, 2013; DO
I: 10.1158/1078-0432.CCR-12-3490 
Figure 2
R
esearch. 
o
n
 M
arch 14, 2014. © 2013 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on August 9, 2013; DO
I: 10.1158/1078-0432.CCR-12-3490 
Figure 3
R
esearch. 
o
n
 M
arch 14, 2014. © 2013 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on August 9, 2013; DO
I: 10.1158/1078-0432.CCR-12-3490 
Figure 4
R
esearch. 
o
n
 M
arch 14, 2014. © 2013 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on August 9, 2013; DO
I: 10.1158/1078-0432.CCR-12-3490 
Figure 5
R
esearch. 
o
n
 M
arch 14, 2014. © 2013 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on August 9, 2013; DO
I: 10.1158/1078-0432.CCR-12-3490 
